Skip to main content

2020

2020-02-11
PRIMARY ENDPOINT REACHED IN THE PHASE 3 STUDY
2020-02-04
STOCKHOLM, February 4[th], 2020 - On February 11[th], 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July - December 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2020-01-22
STOCKHOLM, January 22[nd], 2020. Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and increased the understanding of the study outcomes. Key conclusions include: i) MOB-015 delivers a very high mycological cure rate that compares favorably to oral antifungal drugs with the added advantage of an earlier onset of action; ii) Confirmation that the proprietary vehicle technology increases the hydration and permeability of the nail plate enabling efficient terbinafine delivery, however  it also confounds the  assessment of clinical cure and complete cure and iii) A likely solution to the problem – a shorter dosing regimen with the potential to deliver superior complete cure rates.
2020-01-14
 Moberg Pharma AB (OMX: MOB) announces that the Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares as a consequence of the redemption in 2019 of shares in Moberg Pharma AB for cash proceeds of SEK 46.50 per share.